Aristotle Capital Boston LLC Has $8.94 Million Stake in Encompass Health Co. (NYSE:EHC)

Aristotle Capital Boston LLC cut its stake in Encompass Health Co. (NYSE:EHC - Free Report) by 7.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,769 shares of the company's stock after selling 8,218 shares during the quarter. Aristotle Capital Boston LLC owned approximately 0.10% of Encompass Health worth $8,937,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. AXA S.A. raised its stake in shares of Encompass Health by 132.6% during the 4th quarter. AXA S.A. now owns 66,866 shares of the company's stock worth $6,175,000 after purchasing an additional 38,117 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its position in Encompass Health by 4.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 17,452 shares of the company's stock valued at $1,612,000 after acquiring an additional 749 shares in the last quarter. Freestone Grove Partners LP acquired a new stake in Encompass Health in the fourth quarter valued at approximately $19,572,000. Schonfeld Strategic Advisors LLC grew its position in Encompass Health by 1,001.3% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 32,060 shares of the company's stock worth $2,961,000 after acquiring an additional 29,149 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Encompass Health by 136.8% during the 4th quarter. AQR Capital Management LLC now owns 689,206 shares of the company's stock worth $63,648,000 after purchasing an additional 398,154 shares during the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Stock Performance

EHC stock traded down $0.52 on Monday, reaching $116.12. 759,782 shares of the company were exchanged, compared to its average volume of 685,605. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. Encompass Health Co. has a 12 month low of $82.74 and a 12 month high of $117.98. The stock's fifty day moving average price is $102.07 and its 200 day moving average price is $99.39. The firm has a market capitalization of $11.69 billion, a PE ratio of 26.04, a PEG ratio of 2.31 and a beta of 0.91.

Encompass Health (NYSE:EHC - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same period last year, the business earned $1.12 earnings per share. The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. On average, research analysts anticipate that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.59%. Encompass Health's dividend payout ratio is currently 14.05%.

Insider Buying and Selling at Encompass Health

In other news, EVP John Patrick Darby sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the completion of the transaction, the executive vice president now directly owns 79,710 shares of the company's stock, valued at approximately $9,149,910.90. This represents a 11.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Andrew L. Price sold 5,042 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at approximately $6,798,129.56. This represents a 6.79 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.00% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Truist Financial reiterated a "buy" rating and issued a $135.00 price objective (up from $116.00) on shares of Encompass Health in a report on Monday, April 28th. UBS Group increased their price objective on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. KeyCorp boosted their target price on Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. StockNews.com downgraded Encompass Health from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Barclays boosted their price objective on shares of Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $120.86.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.